NEW YORK, Jan. 13, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Enfusion, Inc. (NYSE: ENFN), relating to the proposed merger with Clearwater Analytics. Under the terms of the agreement, Enfusion shareholders will receive $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock.

NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Sept. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

Los Angeles, Aug. 12, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE: ENFN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Enfusion reported its financial results for the second quarter of 2024 on August 6, 2024. The Company missed consensus estimates for both earnings and revenue. Based on this news, shares of Enfusion fell by 7.86% on the same day.

NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.